Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase EARLY_PHASE1 1Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 161Neoplasms 95Prostatic Neoplasms 86Glioblastoma 76Multiple Myeloma 65Pancreatic Neoplasms 64Glioma 61Brain Neoplasms 56Lung Neoplasms 46Carcinoma, Hepatocellular 45Melanoma 43Head and Neck Neoplasms 43Recurrence 42Carcinoma, Non-Small-Cell Lung 41Leukemia, Myeloid, Acute 40Colorectal Neoplasms 39Squamous Cell Carcinoma of Head and Neck 35Ovarian Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 29Lymphoma 28Carcinoma, Renal Cell 28Polycystic Ovary Syndrome 27Stomach Neoplasms 24Hematologic Neoplasms 23Lymphoma, B-Cell 22Sarcoma 21Endometrial Neoplasms 20Uterine Cervical Neoplasms 19

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Hemangioblastoma × Clear all
NCT01015300 2012-05-11

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Dartmouth-Hitchcock Medical Center

Phase EARLY_PHASE1 Terminated
1 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡